Citable filing context
BMY's research view summarizes recent SEC filing context, starting with earnings from Jul 30, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 30, 2026 | earnings | Bristol Myers Squibb reported Q2 2026 revenue of $13.0 billion and raised its full-year 2026 EPS guidance. |
| May 8, 2026 | other | Bristol-Myers Squibb shareholders elected directors, approved executive compensation, and a 2026 stock award plan at the annual meeting. |
| Apr 30, 2026 | earnings | Bristol Myers Squibb reported Q1 2026 revenues of $11.5 billion and non-GAAP EPS of $1.58. |
| Jul 30, 2026 | Guidance: eliquis_worldwide_revenue_growth | 20.00 to 25.00 |
| Jul 30, 2026 | Guidance: non_gaap_eps | 6.75 to 7.00 |
| Jul 30, 2026 | Guidance: operating_expenses | not reported to 16500.00 |
| Jul 30, 2026 | mda_quarterly | Bristol-Myers Squibb (BMY) reported total revenues of $12.97 billion for the second quarter of 2026, a 6% increase year-over-year, driven by strong demand in its Growth Portfolio and Eliquis, which offset generic erosion in the Legacy Portfolio. Key growth drivers included Reblozyl (up 29%), Breyanzi (up 41%), and Camzyos (up 60%). Conversely, Legacy products like Revlimid and Pomalyst/Imnovid faced significant declines due to generic competition. The company’s GAAP diluted EPS rose to $1.62 from $0.64 in the prior-year period, largely due to the absence of significant one-time acquired IPRD charges that impacted 2025. Operating expenses were influenced by a $420 million IPRD impairment charge and a $220 million priority review voucher purchase, partially mitigated by ongoing strategic productivity initiatives targeting $2 billion in annual cost savings by 2027. BMY continues to face regulatory headwinds, specifically the Inflation Reduction Act (IRA), which has led to price negotiations for Eliquis, Pomalyst, and Orencia. The company is actively defending its intellectual property against generic entrants for Eliquis and Camzyos. Strategic business development remains a priority, highlighted by a new global collaboration with Hengrui to develop 13 early-stage oncology, hematology, and immunology assets. BMY maintains a solid liquidity position, ending the quarter with $11.46 billion in cash and marketable securities. |
| Apr 30, 2026 | mda_quarterly | Bristol-Myers Squibb reported a 3% increase in total revenues to $11.49 billion for Q1 2026, or 1% excluding foreign exchange impacts. GAAP diluted EPS rose to $1.31, driven by lower amortization of acquired intangible assets, though partially offset by higher IPRD impairment charges and the expiry of diabetes royalty income. Non-GAAP EPS decreased to $1.58, primarily due to the diabetes royalty expiry. The Growth Portfolio saw strong performance from Opdivo Qvantig, Camzyos, Breyanzi, Reblozyl, Opdualag, Sotyktu, and Cobenfy, all experiencing significant demand-driven increases. Eliquis revenues grew 16% due to U.S. demand, but faces generic competition in Europe and the Inflation Reduction Act's (IRA) "maximum fair price" in U.S. Medicare. Legacy products like Revlimid, Pomalyst/Imnovid, Sprycel, and Abraxane experienced substantial declines due to generic erosion. Research and development expenses increased 17%, largely due to $410 million in IPRD impairment charges for a radiopharmaceutical and an oncology asset. Amortization of acquired intangible assets decreased significantly as Pomalyst was fully amortized. The company's strategic productivity initiative aims for $2.0 billion in annual cost savings by 2027. The IRA continues to pose a risk, with Eliquis, Pomalyst, and Orencia subject to government-set prices or negotiation. Operating cash flow decreased due to lower Eliquis customer receipts and higher litigation disbursements. |
Source: SEC EDGAR filing text and events; period Jul 30, 2026; filed Jul 30, 2026.
BMY company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.